Service de rhumatologie, hôpital Sud, 16, boulevard de Bulgarie, 35203 Rennes cedex, France.
Joint Bone Spine. 2009 Dec;76(6):595-601. doi: 10.1016/j.jbspin.2009.10.001.
The prevalence of osteoporosis increases with advancing age. Fractures are more common in women than in men and, apart from the menopause, the reasons for this difference remain poorly understood. The growth period is crucial to skeletal development and results in larger bones in males than in females. The sudden drop in estrogen levels that characterizes the menopause contrasts with the gradual decline in sex hormones seen in aging men, and the proportion of individuals with hypogonadism is considerably lower among older men than among older women. Although estrogens play a crucial role in bone homeostasis in both men and women, via direct and indirect mechanisms, differences exist between the sexes in hormonal physiopathology and its consequences on bone tissue. Many genetic and environmental factors influence the fracture risk. Although women are more prone to fractures, the mortality rate associated with fractures is higher in men. Most of the osteoporosis medications were developed for the treatment of postmenopausal osteoporosis and some are licensed for use only in women. Overall, the diagnosis of osteoporosis is somewhat less neglected than previously, but the treatment of high-risk individuals (those with a history of fracture) remains inadequate, most notably among males.
骨质疏松症的患病率随年龄增长而增加。骨折在女性中比男性更常见,除了绝经期外,其原因仍知之甚少。生长时期对骨骼发育至关重要,导致男性的骨骼比女性大。绝经以雌激素水平的突然下降为特征,与衰老男性中逐渐下降的性激素形成对比,而且性腺功能减退症在老年男性中的比例明显低于老年女性。尽管雌激素通过直接和间接机制在男性和女性的骨骼稳态中发挥关键作用,但性别之间在激素病理生理学及其对骨骼组织的影响方面存在差异。许多遗传和环境因素影响骨折风险。尽管女性更容易发生骨折,但男性骨折相关死亡率更高。大多数骨质疏松症药物都是为治疗绝经后骨质疏松症而开发的,有些药物仅获准在女性中使用。总体而言,骨质疏松症的诊断比以前有所减少,但高风险人群(有骨折病史的人群)的治疗仍不充分,尤其是在男性中。